Adagene Inc.

NasdaqGM:ADAG Stock Report

Market Cap: US$243.8m

Adagene Future Growth

Future criteria checks 0/6

Adagene's earnings are forecast to decline at 23% per annum while its annual revenue is expected to grow at 14% per year. EPS is expected to decline by 11.2% per annum. Return on equity is forecast to be -136% in 3 years.

Key information

-23.0%

Earnings growth rate

-11.21%

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate14.0%
Future return on equity-135.95%
Analyst coverage

Low

Last updated08 Apr 2026

Recent future growth updates

Recent updates

Analysis Article • Oct 10

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Adagene Inc. ( NASDAQ:ADAG ) shareholders would be excited to see that the share price has had a great month, posting a...
Analysis Article • Oct 05

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

The latest analyst coverage could presage a bad day for Adagene Inc. ( NASDAQ:ADAG ), with the analysts making...
Seeking Alpha • Aug 30

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Adagene ADR press release (NASDAQ:ADAG): 1H GAAP EPS of -$0.87 misses by $0.45. Revenue of $3.93M (+189.0% Y/Y) misses by $9.82M. Financial Outlook of 2023. ADG116 phase 2a proof-of-concept data from combination dose expansion cohorts. ADG126 phase 2a proof-of-concept data from combination dose expansion cohorts Establish registration path and strategy (e.g., recommended phase 2 dose, indication and design) for phase 2/3 pivotal trial of anti-CTLA-4 in combination with anti-PD-1 therapy in targeted tumors Initiate patient dosing in ADG206 phase 1 trial Submit IND or equivalent for ADG153, and initiate phase 1 trial Results from IIT combination studies of ADG106 Additional collaborations and/or technology licensing agreements
Seeking Alpha • Jun 29

Micro-cap Adagene surges after hours on $10M share buyback

Adagene (NASDAQ:ADAG) on Wednesday authorized a share buyback of up to $10M of its U.S.-listed shares. The micro-cap company's stock surged ~30% to $2.72 in aftermarket trading. ADAG said it expects to use its existing funds to fund repurchases made under the share buyback program. ADAG stock has tumbled nearly 89% from its IPO price of $19.

Earnings and Revenue Growth Forecasts

NasdaqGM:ADAG - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20287-55-63-634
12/31/20272-40-55-555
12/31/2026N/A-31-46-464
12/31/20258-18-16-16N/A
9/30/20254-24-22-22N/A
6/30/20250-30-27-27N/A
3/31/20250-32-29-29N/A
12/31/20240-33-30-30N/A
9/30/20240-33-29-29N/A
6/30/20241-32-28-28N/A
3/31/20249-25-29-28N/A
12/31/202318-19-29-28N/A
9/30/202320-28N/AN/AN/A
6/30/202323-36N/AN/AN/A
3/31/202316-58N/AN/AN/A
12/31/20229-80-49-49N/A
9/30/202211-82N/AN/AN/A
6/30/202213-84N/AN/AN/A
3/31/202211-78N/AN/AN/A
12/31/202110-73-46-43N/A
9/30/20216-68N/AN/AN/A
6/30/20212-62N/AN/AN/A
3/31/20211-52N/AN/AN/A
12/31/20201-43-29-29N/A
9/30/20201-34-27-26N/A
6/30/20201-28-21-21N/A
3/31/20201-22-20-20N/A
12/31/20190-17-18-18N/A
12/31/20182-14N/A-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADAG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ADAG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ADAG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ADAG is forecast to have no revenue next year.

High Growth Revenue: ADAG is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ADAG is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/11 12:33
End of Day Share Price 2026/05/11 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adagene Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
Paul JengGuggenheim Securities, LLC
Yu HeH.C. Wainwright & Co.